From: The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications
Immune cells regulators | SUMO-related participants | Mechanisms | Refs |
---|---|---|---|
PKM2 | UBC9 | Promote macrophage differentiation and TME remodeling through ectosomal excretion | [51] |
IRF4 | UBC9 | Promote Treg cell proliferation and function upon TCR stimulation | [161] |
BACH2 | SENP3 | Promote Treg cell stability maintenance via suppression of BACH2 SUMOylation and its nuclear export | [162] |
NFATc1/IL-2 | UBC9, PIAS1 | Inhibit Treg expansion and promote autoimmunity through inhibiting IL-2 production | [163] |
IL-7 | UBC9 | Promote T cells positive selection and late-stage maturation via maintaining CD8 single-positive cells survival | [165] |
SLP-76 | UBC9 | Promote T cell activation via increasing IL-2 transcription | [166] |
JunB/IL-2 | UBC9 | Promote T cell function via augmenting IL-2 and IL-4 expression | [167] |
RORγt | SUMO3, PIAS4 | Promote TH17 cells differentiation via maintaining its transcriptional activity by recruiting KAT2A and stabilizing the binding of SRC1 | [168] |
PLC-γ1 | SUMO1, PIASxβ/3 | Promote T cell activation through PLC-γ1 microclusters assembly | [169] |
PKC-θ | PIAXxβ | Promote immune synapse formation and T cell activation | [170] |
STAT5 | SENP1 | Promote early lymphoid precursors development via activating STAT5 signaling | [171] |
Blimp-1 | PIAS1 | Promote plasma cells differentiation via enhancing interaction with HDAC2 | [174] |
DAXX | UBC9, SUMO1 | Inhibit B cell development via nucleus localization and proper combination to PML oncogenic domains. |